InSysBio to upgrade its Cytocon DB

NEWS
Software
October 16, 2020

October 16, 2020

Latest news about Cytocon DB! Its new version 1.3.6.8 got a number of principal update

New annotation and review forms were implemented in backend of the database in order to promote “Special units” concept. This tool allows to include into the DB such kind of units for cell subtypes as % of cells_markers_tissue_disease (percent of “parent” cell characterized by particular set of markers) and to recalculate them to unified units whether cells concentration was measured in the annotated article or not. In the first case, the concentration of cell subtypes is calculated on the basis of the concentration of “parent” cell available in the article. In the second case, the average concentration of the “parent” cell in the particular tissue and disease is taken from the DB.

The order of the columns with patient group attributes was changed in the Table results to make data interpretation more convenient.

The DB was extended with new data, namely:

  • 7 diseases,
  • 1 tissue,
  • 26 molecules and
  • 1866 concentrations were introduced,
  • 28 articles were reviewed.

The table shows the actual number of components available in Cytocon DB 1.3.6.8.

To get more information about the latest version of Cytocon DB, please, visit its website.

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

August 2020
MoTuWeThFrSaSu
     
1
2
3
1. 03 Aug 2020 16:00 InSysBio to share new data in frames of its Open Source QSP model of COVID-19 InSysBio has received a new set of results in framework of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
4
5
6
1. 06 Aug 2020 17:51 InSysBio to update its Cytocon DB and to present version 1.2.6.6 InSysBio is glad to present Cytocon DB 1.2.6.6! Cytocon DB team has reviewed 39 articles to introduce new data. It should be outlined that the total number of concentrations within the Database has already exceeded 10 thousand!
7
8
9
10
11
12
13
14
15
16
17
18
19
20
1. 20 Aug 2020 17:18 InSysBio to present the new version of Immune Response Template IRT 3.2.0 acquires new models and extended annotations (Moscow – 20.08.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents the new version of its Immune Response Template (IRT). IRT is an efficient and useful tool to boost and facilitate the development of QSP models in immunology and immuno-oncology therapeutic areas. By this point IRT has been developed into a fully-fledged database but InSysBio constantly goes further in its software advancement.
21
22
23
24
25
26
27
28
29
30
31
      
Upcoming Events
18.10
InSysBio to participate in ACoP 2025
Tags
Latest News
19.08
InSysBio to publish the new article "Revolutionizing drug discovery: Integrating artificial intelligence with quantitative systems pharmacology"
05.08
InSysBio to launch Immune Response Template Open for QSP modeling
25.06
InSysBio to announce extension of collaboration with discoveric bio alpha
18.06
InSysBio to publish the new article in CPT: Pharmacometrics & Systems Pharmacology
03.06
InSysBio to present Integration of Cytocon DB and fIVE DB with Heta for QSP modeling